NRG GY006: Phase III Randomized RT & Cisplatin (impedes DNA synthesis) Alone or in Combo with Intravenous Triapine (impedes DNA synthesis) for Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA CA of the Cervix or Stage II-IVA Vaginal CA (PI: Brown) Link

KEY
- Open to Accrual
- Enrollment on Hold
- Immuno Oncology
- Supportive Care/Non TX

LOCATIONS
- HARTFORD
- HOCC
- MIDSTATE
- BACKUS
- WINDHAM
- AVON
- MANCHESTER
- WATERFORD

Version Date: 201216
Coordinator(s):
Siobhan Reilly | Siobhan.reilly@hhchealth.org | 860 696 4958
Leah Persky | Leah.Persky@hhchealth.org | 860 972 5026
Endometrial Early Stage

Endometrial Advanced/Recurrent

NRG GY018: Phase III, Randomized, Placebo-controlled study of addition of Pembrolizumab (anti PD-1) to the Usual Chemo Tx (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CA (PI: Palisoul) [Link]

MSK-17-180: Phase II, Single Agent Nivolumab (anti PD-1) for selected Uterine CA (PI: Brown) [Link]

KEY
- Immuno Oncology
- Enrollment on Hold
- Pipeline/Opening Soon
- Supportive Care/Non TX

LOCATIONS
- HARTFORD
- WINDHAM
- HOCC
- AVON
- MIDSTATE
- MANCHESTER
- BACKUS
- WATERFORD

Version Date: 201216
Coordinator(s):
Siobhan Reilly | Siobhan.reilly@hhchealth.org | 860 696 4958
Leah Persky | Leah.Persky@hhchealth.org | 860 972 5026
Ovarian/Fallopian/Peritoneal

Newly Diagnosed

Platinum-Sensitive

- D6018C00004: Phase II, 2nd Maintenance Treatment in Pts with Platinum Sensitive Relapsed Epithelial Ovarian CA, & previously received PARP Inhibitor Maintenance Treatment (Pl: Palisoul) [Link]

Recurrent

Platinum-Resistant

- GOG 3018/VBL-111-701 OVAL Phase III, Randomized, to compare VB-111 (adenovirus vector) & paclitaxel (antimitotic agent) to placebo & paclitaxel in adults with Recurrent Platinum-Resistant Ovarian CA (Pl: Brown) [Link]

- NRG-GY009: Phase II/III Randomized Pegylated Liposomal Doxorubicin Hydrochloride (topoisomerase II inhibitor) With Atezolizumab (anti PD-1) and/or Bevacizumab (VEGF inhibitor) in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Pl: Cosin) [Link]

KEY
- Open to Accrual
- Enrollment on Hold
- Immuno Oncology
- Pipeline/Opening Soon
- Supportive Care/Non TX

LOCATIONS
- HARTFORD
- HOCC
- MIDSTATE
- BACKUS
- WINDHAM
- AVON
- MANCHESTER
- WATERFORD

Version Date: 201216
Coordinator(s):
Siobhan Reilly | Siobhan.reilly@hhchealth.org | 860 696 4958
Leah Persky | Leah.Persky@hhchealth.org | 860 972 5026
GYNECOLOGY

Nontreatment

**Other**

**Genomic**

- **MSK 12-245 IMPACT**
  Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy – IMPACT
  (PI: Salner)
  [Link]

**Surgical**

- **NRG CC008**
  NON-randomized prospective Compr 2 Surgical Procedures for BRCA1 Mutations to Assess Reduced Risk of Ovarian CA
  [SOROC]
  (PI: Palsoul)
  [Link]

**Observational**

- **SURG19-013/ 20-067: SEntinel Lymph node Endometrial Cancer Trial:** Prospective Multicenter International Single-Arm Observational Trial (SELECT.)
  (PI: Cosin)
  [Link]

**KEY**

- Open to Accrual
- Enrollment on Hold
- Immuno Oncology
- Pipeline/Opening Soon
- Supportive Care/Non TX

**LOCATIONS**

- HARTFORD
- HOCC
- MIDSTATE
- BACKUS
- WINDHAM
- AVON
- MANCHESTER
- WATERFORD

Version Date: 201216
Coordinator(s):
Siobhan Reilly | Siobhan.reilly@hhchealth.org | 860 696 4958
Leah Persky | Leah.Persky@hhchealth.org | 860 972 5026

IMPACT: Susanne Morrill | susanne.morrill@hhchealth.org | 860-972-1588
NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin (PI: Palisoul) [Link]